​

Anbio Biotechnology Class A Ordinary Shares (NNNN) Revenue & Revenue Breakdown

OverviewFinancialsChart

Anbio Biotechnology Class A Ordinary Shares Revenue Highlights

Latest Revenue (Y)

$8.19M

Latest Revenue (Q)

$2.53M

Anbio Biotechnology Class A Ordinary Shares Revenue by Period

Anbio Biotechnology Class A Ordinary Shares Revenue by Year

DateRevenueChange
2024-12-31$8.19M21.95%
2023-12-31$6.71M-71.49%
2022-12-31$23.54M431.67%
2021-12-31$4.43M-

Anbio Biotechnology Class A Ordinary Shares generated $8.19M in revenue during NA 2024, up 21.95% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Anbio Biotechnology Class A Ordinary Shares Revenue by Quarter

DateRevenueChange
2024-12-31$2.53M-60.01%
2024-06-30$6.32M60.04%
2023-12-31$3.95M19.49%
2023-06-30$3.31M-

Anbio Biotechnology Class A Ordinary Shares generated $2.53M in revenue during Q4 2024, up -60.01% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Anbio Biotechnology Class A Ordinary Shares Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
CYHCommunity Health Systems$12.63B$3.09B
SNDLSNDL$909.01M$197.75M
AVNSAvanos Medical$687.80M$177.80M
ANGOAngioDynamics$292.50M$75.71M
TALKTalkspace$187.59M$59.38M
RIGLRigel Pharmaceuticals$179.28M$69.46M
GOSSGossamer Bio$114.70M$13.29M
CLPTClearPoint Neuro$31.39M$8.86M
NNNNAnbio Biotechnology Class A Ordinary Shares$8.19M$2.53M
KALVKalVista Pharmaceuticals-$13.69M
CMPSCOMPASS Pathways--

NNNN Revenue FAQ

What is Anbio Biotechnology Class A Ordinary Shares’s yearly revenue?

Anbio Biotechnology Class A Ordinary Shares's yearly revenue for 2024 was $8.19M, representing an increase of 21.95% compared to 2023. The company's yearly revenue for 2023 was $6.71M, representing a decrease of -71.49% compared to 2022. NNNN's yearly revenue for 2022 was $23.54M, representing an increase of 431.67% compared to 2021.

What is Anbio Biotechnology Class A Ordinary Shares’s quarterly revenue?

Anbio Biotechnology Class A Ordinary Shares's quarterly revenue for Q4 2024 was $2.53M, a -60.01% decrease from the previous quarter (Q2 2024). The company's quarterly revenue for Q2 2024 was $6.32M, a 60.04% increase from the previous quarter (Q4 2023). NNNN's quarterly revenue for Q4 2023 was $3.95M, a 19.49% increase from the previous quarter (Q2 2023).

What is Anbio Biotechnology Class A Ordinary Shares’s revenue growth rate?

Anbio Biotechnology Class A Ordinary Shares's revenue growth rate for the last 3 years (2022-2024) was -65.24%